Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Short Report
  • Published:

Sustained activation of the Raf/MEK/Erk pathway in response to EGF in stable cell lines expressing the Hepatitis C Virus (HCV) core protein

Abstract

Chronic hepatitis C virus (HCV) infection is a leading cause of liver cirrhosis and hepatocellular carcinoma (HCC) worldwide. The HCV capside core is a multifunctional protein with regulatory functions that affects transcription and cell growth in vitro and in vivo. Here, we show that both HCV genotype 1a and 3 core proteins activate MEK1 and Erk1/2 MAP kinases and that the costitutive expression of the HCV core results in a high basal activity of Raf1 and MAP/kinase/kinase, as determined by endogenous Raf1 in vitro kinase assay and immunodetection of hyperphosphorylated Erk1 and Erk2 even after a serum starvation. Moreover, the activation of both Erk1/2 and the downstream transcription factor Elk-1 in response to the mitogenic stimulus EGF is significantly prolonged. The sustained response to EGF in cells expressing the HCV core occurs despite a normal induction of the MAP phosphatases MKP regulatory feedback and is likely due to the costitutive activation of Raf-1 activity. The ability of HCV core proteins to directly activate the MAP kinase cascade and to prolong its activity in response to mitogenic stimuli may contribute to the neoplastic transformation of HCV infected liver cells.

This is a preview of subscription content, access via your institution

Access options

Buy this article

Prices may be subject to local taxes which are calculated during checkout

Figure 1
Figure 2

Similar content being viewed by others

References

  • Aoki H, Hayashi J, Moriyama M, Arakawa Y, Hino O . 2000 J. Virol. 74: 1736–1741

  • Barba G, Harper F, Harada T, Kohara M, Goulinet S, Matsuura Y, Eder G, Schaff ZS, Chapman MJ, Myamura T, Brechot C . 1997 Proc. Natl. Acad. Sci. USA 94: 1200–1205

  • Brondello JM, Pouyssegur J, McKenzie FR . 1999 Science 286: 2514–2517

  • Bruno S, Silini E, Crosignani A, Borzio F, Leandro G, Bono F, Asti M, Rossi M, Larghi A, Cerino A, Podda M, Mondelli MU . 1997 Hepatology 25: 754–758

  • Cacciola I, Pollicino T, Squadrito G, Cerenzia G, Orlando ME, Raimondo G . 1999 N. Engl. J. Med. 341: 22–26

  • Colombo M . 1999 J. Hepatol. 31: 25–30

  • De Francesco R . 1999 J. Hepatol. 31: 47–53

  • Donato F, Boffetta P, Puoti M . 1998 Int. J. Cancer 30: 347–354

  • Doria M, Klein N, Lucito R, Schneider RJ . 1995 EMBO J. 14: 4747–4757

  • Garrington TP, Johnson GL . 1999 Curr. Opin. Cell. Biol. 11: 211–218

  • Hayashi J, Aoki H, Arakawa Y, Hino O . 1999 Intervirology 42: 205–210

  • Hayashi J, Aoki H, Kajino K, Moriyama M, Arakawa Y, Hino O . 2000 Hepatology 32: 958–961

  • Ito Y, Sasaki Y, Horimoto M, Wada S, Tanaka Y, Kasahara A, Ueki T, Hirano T, Yamamoto H, Fujimoto J, Okamoto E, Hayashi N, Hori M . 1998 Hepatology 27: 951–958

  • Jin DY, Wang HL, Zhou Y, Chun AC, Kibler KV, Hou YD, Kung H, Jeang K-T . 2000 EMBO J. 19: 729–740

  • Kalkuhl A, Troppmair J, Buchmann A, Stinchcombe S, Buenemann CL, Rapp UR, Kaestner K, Schwarz M . 1998 Hepatology 27: 1081–1088

  • Klein NP, Schneider R . 1997 Mol. Cell. Biol. 17: 6427–6436

  • Lu W, Lo S, Chen M, Wu K, Fung YK, Ou J . 1999 Virology 264: 134–141

  • Mamiya N, Worman HJ . 1999 J. Biol. Chem. 274: 15751–15756

  • McKillop IH, Schmidt CM, Cahill PA, Sittzmann JV . 1997 Hepatology 26: 1484–1491

  • Moriya K, Yotsuyanagi H, Shintani Y, Fujie H, Ishibashi K, Matsuura Y, Miyamura T, Koike K . 1997 J. Gen. Virol. 78: 1527–1531

  • Moriya K, Fujie H, Shintani Y, Yotsuyanagi H, Tsutsumi T, Ishibashi K, Matsuura Y, Kimura S, Miyamura T, Koike K . 1998 Nat. Med. 9: 1065–1067

  • Morrison DK, Cuttler Jr RE . 1997 Curr. Opin. Cell Biol. 9: 174–179

  • Natoli G, Avantaggiati ML, Chirillo PL, Ianni A, Balsano C, Levrero M . 1994 Oncogene 9: 2837–2848

  • Ray RB, Meyer K, Ray R . 2000 Virology 271: 197–204

  • Schaeffer H, Weber M . 1999 Mol. Cell. Biol. 19: 2435–2444

  • Schmidt CM, McKillop IH, Cahill PA, Sitzmann JV . 1997 Biochem. Biophys. Res. Commun. 236: 54–58

  • Shibata Y, Nakata K, Tsuruta S, Hamasaki K, Hayashida Y, Kato Y, Nakao K, Eguchi K . 1999 Int. J. Oncol. 14: 1153–1156

  • Shrivastava A, Manna SK, Ray R, Aggarwal BB . 1998 J. Virol. 72: 9722–9728

  • Tamori A, Nishiguchi S, Kubo S, Koh N, Moriyama Y, Fujimoto S, Takeda T, Shiomi S, Hirohashi K, Kinoshita H, Otani S, Kuroki T . 1999 Hepatology 29: 1429–1434

  • Tsuchihara K, Hijikata M, Fukuda K, Kurori T, Yamamoto N, Shimotohno K . 1999 Virology 258: 100–107

  • You L, Chen C, Yeh T, Tsai T, Mai R, Lin C, Lee Y . 1999 J. Virol. 73: 2841–2853

Download references

Acknowledgements

This work was supported by a MURST-Cofin grant to C Balsano, and by grants from AIRC, ISS-Viral Hepatitis Project and Schering-Plough to M Levrero. Francesca Covone was supported by a fellowship from the Fondazione A Cesalpino.

Author information

Authors and Affiliations

Authors

Rights and permissions

Reprints and permissions

About this article

Cite this article

Giambartolomei, S., Covone, F., Levrero, M. et al. Sustained activation of the Raf/MEK/Erk pathway in response to EGF in stable cell lines expressing the Hepatitis C Virus (HCV) core protein. Oncogene 20, 2606–2610 (2001). https://doi.org/10.1038/sj.onc.1204372

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.onc.1204372

Keywords

This article is cited by

Search

Quick links